$1250 | Single User
$1800 | Site License
$2500 | Global License

Global Type 1 Diabetes (T1D) Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 10 Jul 2018 | 270534 | In Stock
Related Topics: Clinical Trials , Diabetes , Drug

Introduction

GervanoRA's Market Estimation report "Diabetes Type-1: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019-2025)" analyzed the current and upcoming opportunities in the Diabetes Type-1 area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Diabetes Type-1 industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Diabetes Type-1 area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Diabetes Type-1 Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Diabetes Type-1 competitive environment. We have also prognosticated the Diabetes Type-1 market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Epidemiology and Epidemiology forecast 2019 - 2025

Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

Estimated Pipeline Drug Approval Timelines

Clinical Trials Summary

Current and Future Competitive Landscape

Key Company Profiles with SWOT Analysis

Emerging Company Profiles with Opportunity Assessments

Pipeline Drug Descriptions along with Development milestones (Past and Future)

University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

Table of Contents
for Global Type 1 Diabetes (T1D) Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)

  • TABLE OF CONTENTS

    1. INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. UPCOMING AND OTHER AVAILABLE REPORTS

    1.4. ABOUT US: GERVANORA DATA SERVICES

    2. EXECUTIVE SUMMARY

    2.1. MARKET SNAPSHOT, 2019-2025

    2.2. KEY EVENTS IN DIABETES TYPE-1 MARKET, 2015-2030

    2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES

    2.4. KEY MAJOR FINDINGS

    2.4.1. DRIVERS

    2.4.2. RESTRAINTS

    2.4.1. UNMET NEEDS AND OPPORTUNITIES

    3. DISEASE OVERVIEW

    3.1. DISEASE DEFINITION & SYMPTOMS

    3.1.1. CLINICAL MANIFESTATIONS

    3.1.2. PATHOGENESIS

    3.2. DISEASE CAUSE AND CLASSIFICATION

    3.3. DISEASE DIAGNOSIS

    3.4. TREATMENT ALGORITHM AND GUIDELINES

    3.5. EPIDEMIOLOGY AND DISEASE BURDEN

    3.6. EPIDEMIOLOGY FORECAST

    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION

    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    4. MARKET OVERVIEW

    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT

    4.2. PRICING AND REIMBURSEMENT

    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010

    4.5. NEW DRUG APPROVALS (EMA) SINCE 2010

    4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION (FILED) MOLECULES

    5.1.2. PHASE 3 MOLECULES

    5.1.3. PHASE 2 MOLECULES

    5.1.4. PHASE 1 MOLECULES

    5.1.5. PRECLINICAL MOLECULES

    5.1.6. EARLY R&D MOLECULES

    5.1.7. INACTIVE AND TERMINATED MOLECULES

    5.2. PIPELINE ANALYSIS BY GEOGRAPHY

    5.2.1. UNMET NEEDS AND OPPORTUNITIES

    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    5.3.1. UNMET NEEDS AND OPPORTUNITIES

    5.4. PIPELINE ANALYSIS BY DRUG CLASS

    5.4.1. UNMET NEEDS AND OPPORTUNITIES

    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION

    5.5.1. UNMET NEEDS AND OPPORTUNITIES

    5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES

    5.7. ESTIMATED APPROVAL TIMELINES

    5.7.1. METHODOLOGY

    5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    6. DIABETES TYPE-1 CLINICAL TRIALS SUMMARY

    6.1. DIABETES TYPE-1 PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS

    6.1.1. KEY PHASE 3 RESULTS

    6.1.2. KEY PHASE 2 RESULTS

    6.2. ONGOING CLINICAL TRIALS SUMMARY

    6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY

    6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY

    6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY

    6.3 PLANNED CLINICAL TRIALS SUMMARY

    6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY

    6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY

    6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY

    6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY

    7. DIABETES TYPE-1 MARKET BY DRUG CLASS

    8. DIABETES TYPE-1 MARKET BY ROUTE OF ADMINISTRATION

    9. DIABETES TYPE-1 MARKET BY GEOGRAPHY

    9.1. UNITED STATES

    9.1.1. MARKET TRENDS AND GROWTH FACTORS

    9.1.2. UNMET NEEDS AND OPPORTUNITIES

    9.1.3. US DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.2. UNITED KINGDOM

    9.2.1. MARKET TRENDS AND GROWTH FACTORS

    9.2.2. UNMET NEEDS AND OPPORTUNITIES

    9.2.3. UK DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.3. GERMANY

    9.3.1. MARKET TRENDS AND GROWTH FACTORS

    9.3.2. GERMANY DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.4. FRANCE

    9.4.1. MARKET TRENDS AND GROWTH FACTORS

    9.4.2. UNMET NEEDS AND OPPORTUNITIES

    9.4.3. FRANCE DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.5. ITALY

    9.5.1. MARKET TRENDS AND GROWTH FACTORS

    9.5.2. UNMET NEEDS AND OPPORTUNITIES

    9.5.3. ITALY DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.6. SPAIN

    9.6.1. MARKET TRENDS AND GROWTH FACTORS

    9.6.2. UNMET NEEDS AND OPPORTUNITIES

    9.6.3. SPAIN DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.7. JAPAN

    9.7.1. MARKET TRENDS AND GROWTH FACTORS

    9.7.2. UNMET NEEDS AND OPPORTUNITIES

    9.7.3. JAPAN DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.8. CHINA

    9.8.1. MARKET TRENDS AND GROWTH FACTORS

    9.8.2. UNMET NEEDS AND OPPORTUNITIES

    9.8.3. CHINA DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.9. INDIA

    9.9.1. MARKET TRENDS AND GROWTH FACTORS

    9.9.2. UNMET NEEDS AND OPPORTUNITIES

    9.9.3. INDIA DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.10. BRAZIL

    9.10.1. MARKET TRENDS AND GROWTH FACTORS

    9.10.2. UNMET NEEDS AND OPPORTUNITIES

    9.10.3. BRAZIL DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.11. RUSSIA

    9.11.1. MARKET TRENDS AND GROWTH FACTORS

    9.11.2. UNMET NEEDS AND OPPORTUNITIES

    9.11.3. RUSSIA DIABETES TYPE-1 MARKET SIZE (2018), FORECAST (2019-2025)

    9.12. ROW

    9.12.1. MARKET TRENDS AND GROWTH FACTORS

    9.12.2. UNMET NEEDS AND OPPORTUNITIES

    9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)

    10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    10.1. COMPANIES

    10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS

    10.1.2. TOP 20 EMERGING COMPANIES IN THE DIABETES TYPE-1 AREA

    10.2. UNIVERSITIES AND INSTITUTES

    11. ABBREVIATIONS LIST OF TABLES

List Of Tables
in Global Type 1 Diabetes (T1D) Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)

LIST OF TABLES:

TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS

TABLE 2: LIST OF FDA APPROVED DRUGS FOR DIABETES TYPE-1

TABLE 3: LIST OF EMA APPROVED DRUGS FOR DIABETES TYPE-1

TABLE 4: DIABETES TYPE-1 EPIDEMIOLOGY (2018), FORECAST (2019-2025)

TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN DIABETES TYPE-1 AREA

TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN DIABETES TYPE-1 AREA

TABLE 7: MAJOR LICENSING AGREEMENTS IN DIABETES TYPE-1 AREA

TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN DIABETES TYPE-1 AREA

TABLE 9: MAJOR GRANTS AND FUNDINGS IN DIABETES TYPE-1 AREA

TABLE 10: MAJOR ALLIANCE DEALS IN DIABETES TYPE-1 AREA

TABLE 11: US FDA APPROVED DRUGS FOR DIABETES TYPE-1 SINCE 2010

TABLE 12: EX-US APPROVED DRUGS FOR DIABETES TYPE-1 SINCE 2010

TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 14: PHASE 3 MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 15: PHASE 2 MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 16: PHASE 1 MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 17: PRECLINICAL MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 18: EARLY R&D MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE DIABETES TYPE-1 DRUG PIPELINE

TABLE 20: DIABETES TYPE-1 DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION

TABLE 21: DIABETES TYPE-1 DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS

TABLE 22: DIABETES TYPE-1 DRUG PIPELINE MOLECULES BY UNIVERSITIES

TABLE 23: DIABETES TYPE-1 DRUG PIPELINE MOLECULES BY INSTITUTES

TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES

TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS

TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS

TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS

TABLE 28: PLANNED CLINICAL TRIALS FOR THE DIABETES TYPE-1 AREA

TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS

TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS

TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS

TABLE 32: GLOBAL DIABETES TYPE-1 MARKET BY DRUG CLASS (2019-2025)

TABLE 33: GLOBAL DIABETES TYPE-1 MARKET BY ROA (2019-2025)

TABLE 34: STRENGTH, DOSAGE AND ROA OF DIABETES TYPE-1 DRUGS

TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF DIABETES TYPE-1 PER YEAR

TABLE 36: GLOBAL DIABETES TYPE-1 MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE DIABETES TYPE-1 AREA

TABLE 50: LIST OF EMERGING COMPANIES IN THE DIABETES TYPE-1 AREA

TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES

TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES

(ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 102 TABLES IN THE REPORT)

List Of Figures, Charts and Diagrams
in Global Type 1 Diabetes (T1D) Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)

LIST OF FIGURES:

FIGURE 1: GLOBAL DIABETES TYPE-1 MARKET 2019-2025: MARKET SNAPSHOT

FIGURE 2: GLOBAL DIABETES TYPE-1 MARKET BY GEOGRAPHY 2018 V/S 2025

FIGURE 3: DIABETES TYPE-1 MARKET BY ROA, 2018

FIGURE 4: DIABETES TYPE-1 MARKET BY AGE GROUP, 2018

FIGURE 5: KEY INFLECTION POINTS IN DIABETES TYPE-1 MARKET (2015-2030)

FIGURE 6: DIABETES TYPE-1 MAJOR FINDINGS

FIGURE 7: MEDICAL EXPENDITURES FOR DIABETES TYPE-1

FIGURE 8: DIABETES TYPE-1 EPIDEMIOLOGY (2018), FORECAST (2019-2025)

FIGURE 9: OVERALL DEALS ACTIVITY IN DIABETES TYPE-1 AREA

FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE

FIGURE 11: DIABETES TYPE-1 DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT

FIGURE 12: DIABETES TYPE-1 DRUG PIPELINE ANALYSIS BY GEOGRAPHY

FIGURE 13: DIABETES TYPE-1 DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES

FIGURE 14: DIABETES TYPE-1 DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 15: DIABETES TYPE-1 DRUG PIPELINE ANALYSIS BY DRUG CLASS

FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD

FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD

FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES

FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL DIABETES TYPE-1 MARKET BY DRUG CLASS

FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL DIABETES TYPE-1 MARKET BY ROA

FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025

FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025

FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025

FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025

FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025

FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025

FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025

FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025

FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025

FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025

FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025

FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025

FIGURE 33: COMPANY FINANCIAL INFORMATION

FIGURE 34: COMPANY SWOT ANALYSIS

(ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 51 FIGURES IN THE REPORT)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270534 | GERPHME142

Number of Pages

285

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
Introduction...Gain new KOL insights on the latest events that have the potential to impact the trea...
01 Apr 2016 by FirstWord Pharma USD $995 More Info
Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM):...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
NPS+ Type 2 Diabetes Mellitus (US)
IntroductionT2DM drug manufacturers: compare your brand to 7 major competitorsHow loyal are doctors ...
01 Dec 2015 by FirstWord Pharma USD $2,495 More Info
NPS+ Type 2 Diabetes Mellitus (EU5)
IntroductionT2DM drug manufacturers: Compare your brand to 7 major competitorsHow loyal are doctors ...
01 Dec 2015 by FirstWord Pharma USD $2,495 More Info
Medical Affairs Reputations (US): Type 2 Diabetes Mellitus
IntroductionWhat do physicians think of U.S. Medical Affairs teams in the Type 2 Diabetes Mellitus (...
01 Sep 2015 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus
IntroductionWhat do physicians think of Europe Medical Affairs teams in the Type 2 Diabetes Mellitus...
01 Sep 2015 by FirstWord Pharma USD $5,995 More Info
Type 2 Diabetes Mellitus: KOL Insight
IntroductionThe market for Type 2 Diabetes therapies is extremely crowded. Several classes, includin...
01 Jul 2015 by FirstWord Pharma USD $7,900 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)
IntroductionWhat environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? F...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)
IntroductionWhat market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to a...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Global Type 1 Diabetes (T1D) Therapeutic Market (Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028) | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...